Dr. Lopez-Bresnahan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15 Parkman St
Neurology Associates
Boston, MA 02114
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1986 - 1990
Brown UniversityResidency, Internal Medicine, 1984 - 1986
New York University School of MedicineClass of 1984
Certifications & Licensure
MA State Medical License 1988 - 2025- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects Start of enrollment: 2001 Jan 01
Publications & Presentations
PubMed
- 3 citationsCognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory ...Thomas R. Kosten, Efrat Aharonovich, Narinder Nangia, Abigail Zavod, Sarah C. Akerman
Addictive Behaviors. 2020-12-01 - 44 citationsDiroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 studyRobert T. Naismith, Jerry S. Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L. Arnold
Multiple Sclerosis. 2020-11-01 - 77 citationsDiroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Scleros...Robert T. Naismith, Annette Wundes, Tjalf Ziemssen, Elzbieta Jasinska, Mark S. Freedman
CNS Drugs. 2020-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
